55
Participants
Start Date
February 29, 2004
Primary Completion Date
January 31, 2006
Study Completion Date
July 31, 2006
Pegylated interferon and ribavirin
Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
Pegylated interferon and ribavirin
Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
Western Hospital, Footscray
Royal Melbourne Hospital, Melbourne
Nepean Hospital, Sydney
St Vincents Hospital, Sydney
Lead Sponsor
The University of New South Wales
OTHER
St Vincent's Hospital, Sydney
OTHER
Western Hospital, Australia
OTHER_GOV
Monash University
OTHER
Hoffmann-La Roche
INDUSTRY
Melbourne Health
OTHER